Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting

@article{VanBelle2008FosaprepitantD,
  title={Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting},
  author={Simon Van Belle and V{\'e}ronique F. Cocquyt},
  journal={Expert Opinion on Pharmacotherapy},
  year={2008},
  volume={9},
  pages={3261 - 3270}
}
Background: This paper reviews the existing literature on fosaprepitant, an intravenous neurokinin-1 anatgonist for the prevention of chemotherapy induced nausea and vomiting. Objectives: To describe the development of fosaprepitant and to situate the intravenous form of aprepitant in the current market of available antiemetics. Methods: Literature was screened and selected in order to compare the intravenous form of the already commonly used NK-1 receptor antagonist aprepitant. Results… 
Aprepitant: a review of its use in the prevention of nausea and vomiting.
TLDR
Oral aprepitant was effective in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with single or multiple cycles of highly emetogenic chemotherapy (HEC) and when combined with a corticosteroid and 5-HT(3) receptor antagonist is a recommended regimen for the treatment of CINV.
The Effect of Aprepitant Regimen on the Prevention of High-Dose Cisplatin-Induced Nausea and Vomiting
TLDR
Compared with standard regimen, addition of aprepitant provided superior prevention against CINV in Korean patients receiving highly emetogenic cisplatin-based chemotherapy as well as in patients who received the standard regimen to prevent CinV in previous chemotherapy cycles.
An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy
TLDR
Fosaprepitant antiemetic therapy causes significant infusion site adverse events (ISAE) that are appreciably higher than previous reports and patients receiving platinum-based chemotherapy appear to have less significant ISAE than do patients who receive anthracycline-based regimens.
The Role of Neurokinin-1 Receptor Antagonists in CINV
TLDR
Improvements in the management of CINV control were achieved with the discovery of 5-hydroxytryptamine (5HT3) receptor and the development of 5HT3 receptor antagonists (RA).
Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?
TLDR
The latest developed 5HT3 receptor antagonist palonosetron led to an update of the guidelines of CINV, and implementation in daily practice seem to be below the optimal level.
Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?
TLDR
The latest developed 5HT3 receptor antagonist palonosetron led to an update of the guidelines of CINV, and implementation in daily practice seem to be below the optimal level.
UVR-B-induced NKR-1 Expression in Ocular Tissues is blocked by Substance P Receptor Antagonist Fosaprepitant in the Exposed as well as Unexposed Partner Eye
TLDR
The clinically approved N KR-1 receptor antagonist Fosaprepitant decreases NKR-1 protein expression effectively not only in the exposed but also in the unexposed partner eye in a UVR-B irradiation mouse model.
Chapter 28 To Market, To Market — 2008
TLDR
Among the cardiovascular and hematological NMEs launched past year, Amgen's recombinant fusion protein known as “Nplate ®” attracted significant attention due to its therapeutic novelty and represented the only first-in-class therapy of the year.
Quality by Design Approach for Development and Validation of Stability Indicating RP-HPLC Method for Fosaprepitant Dimeglumine
Quality by design approach has been used to develop simple, rapid, sensitive gradient RP-HPLC stability indicating method for fosaprepitant dimeglumine and its related impurities. The chromatographic

References

SHOWING 1-10 OF 89 REFERENCES
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
TLDR
A single dose of L-758,298 substantially suppressed the delayed nausea and vomiting characteristic of high dose cisplatin and also appeared to reduce acute emesis post-cisplatin, supporting the proposition that the underlying mechanism(s) of acute and delayed emesis are different.
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
TLDR
The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin and combined with granisetron plus dexamethasone improves the prevention of acute emesis.
Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets.
TLDR
Analysis of the pharmacokinetics, metabolism, and brain penetration of the neurokinin 1 (NK1) receptor antagonist (substance P receptor antagonist), aprepitant, in ferrets suggested that aprepant, rather than its metabolites, was responsible, primarily, for the antiemetic activity of this compound in the male ferret.
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
TLDR
A 57-year-old woman presented with a metastatic osteosarcoma of the left calcaneum and received her first cycle of treatment combining ifosfamide, the first neurokinin-1 receptor antagonist, and a new antiemetic indicated for highly and moderately emetogenic chemotherapy, in association with 5-HT3 receptor antagonists and corticosteroids.
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients
TLDR
As the aprepitant antiemetic regimen has no detectable inhibitory or inductive effect on the pharmacokinetics of vinorelbine, aprepant when added to a standard antiemetics regimen consisting of ondansetron and dexamethasone can be safely combined with vinorlbine at clinically recommended doses.
The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
TLDR
Data show that MK-0869 and its prodrug, L-758,298, have good activity against cisplatin-induced emesis in ferrets and provided a basis for the clinical testing of these agents for the treatment of emesis associated with cancer chemotherapy.
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
  • P. Hesketh, S. Grunberg, +11 authors K. Horgan
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.
Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.
TLDR
Several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies.
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
TLDR
Concomitant administration of aprepitant had no clinically significant effect on the mean pharmacokinetic characteristics of either ondansetron or granisetron in these healthy subjects.
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
  • D. Campos, J. R. Pereira, +9 authors B. Gertz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
Once daily oral administration of MK-869 was effective in reducing delayed emesis and nausea after high-dose cisplatin, however, the combination of the 5HT3 antagonist plus dexamethasone was numerically superior to MK- 869 plus DexamethAsone in reducing acute emesis.
...
1
2
3
4
5
...